Liposome-containing composition for cosmetics, and cosmetics

Abstract

To provide a liposome-containing composition for a cosmetic which comprises a liposome with a high inclusion rate of the content and a cosmetic using the liposome-containing composition for a cosmetic.SOLUTION: There are provided: a liposome-containing composition for a cosmetic comprising a liposome and a dispersant for dispersing the liposome, wherein the liposome contains one or more compounds A selected from the group consisting of stearyl glycyrrhetinate, a polyoxyethylene phytosterol, cholesterol and phytosterol other than the polyoxyethylene phytosterol and lecithin and includes a liposome having a single lamellar structure; and a cosmetic containing the liposome-containing composition for a cosmetic.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present disclosure relates to a liposome-containing composition for cosmetics and a cosmetic. [Background technology]

[0002] Liposomes are closed endoplasmic reticulum formed by a lipid bilayer containing lipids such as lecithin, and can encapsulate substances inside the closed endoplasmic reticulum. Liposomes are usually present in a dispersed state in a dispersion medium.

[0003] Patent Document 1 proposes a cosmetic composition that contains a hydrogenated phospholipid and at least one surfactant selected from the group consisting of polyoxyethylene hydrogenated castor oil having an average number of moles of ethylene oxide added of 40 to 95, PPG-6 decyltetradeceth-30, and PEG-20 phytosterol, and that contains liposomes encapsulating an oil or fat component. Patent Document 2 proposes a liposome composition containing a phosphatidyl ester of a hydroxy fatty acid as a membrane-constituting lipid as a composition applicable to cosmetics. Patent Document 3 proposes a composition containing a disc-shaped bicelle structure formed by a lipid bilayer membrane as a composition applicable to cosmetics. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Japanese Patent Application Publication No. 2020-093992 [Patent Document 2] Japanese Patent Application Laid-Open No. 2002-145721 [Patent Document 3] Japanese Patent Publication No. 2020-019764 Summary of the Invention [Problem to be solved by the invention]

[0005] When liposomes are used in cosmetics, liposomes that can encapsulate larger amounts of substances such as cosmetic ingredients are desired.

[0006] The present disclosure has been made in consideration of the above circumstances. An object of one embodiment of the present disclosure is to provide a liposome-containing cosmetic composition containing liposomes with a high encapsulation rate of an encapsulated substance. Another problem to be solved by another embodiment of the present disclosure is to provide a cosmetic using the liposome-containing composition for cosmetics. [Means for solving the problem]

[0007] The present disclosure includes the following aspects. [1] A composition comprising a liposome and a dispersion medium for dispersing the liposome, the liposome contains stearyl glycyrrhetinate, polyoxyethylene phytosterol, one or more compounds A selected from the group consisting of cholesterol and phytosterols other than the polyoxyethylene phytosterol, and lecithin, and the liposome has a single lamellar structure; Liposome-containing cosmetic composition. [2] The liposome-containing composition for cosmetics according to [1], wherein the liposomes have an average particle size of 100 nm to 350 nm. [3] The liposome-containing composition for cosmetics according to [1] or [2], wherein the average number of moles of oxyethylene groups added in the polyoxyethylene phytosterol is 5 to 30. [4] The liposome-containing composition for cosmetics according to any one of [1] to [3], wherein the content of the polyoxyethylene phytosterol is 3% by mass to 14% by mass relative to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin. [5] The liposome-containing composition for cosmetics according to any one of [1] to [4], wherein the content of the stearyl glycyrrhetinate relative to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin is 0.3% by mass to 0.7% by mass. [6] The liposome-containing composition for cosmetics according to any one of [1] to [5], wherein the ratio of the content of the compound A to the content of the stearyl glycyrrhetinate is 10 to 60 by mass. [7] The liposome-containing composition for cosmetics according to any one of [1] to [6], wherein the ratio of the content of the polyoxyethylene phytosterol to the total content of the stearyl glycyrrhetinate and the compound A is 0.15 to 0.66 by mass. [8] The liposome-containing composition for cosmetics according to any one of [1] to [7], wherein the ratio of the total content of the polyoxyethylene phytosterol and the compound A to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin is 24% by mass to 27% by mass. [9] The liposome-containing composition for cosmetics according to any one of [1] to [8], wherein the liposome encapsulates a cosmetic ingredient.

[10] The liposome-containing composition for cosmetics according to [9], wherein the cosmetic ingredient is a water-soluble cosmetic ingredient.

[11] The liposome-containing composition for cosmetics according to [9] or

[10] , wherein the cosmetic ingredient is one or more cosmetic ingredients selected from the group consisting of tranexamic acid and Sanguisorba officinalis extract.

[12] The liposome-containing composition for cosmetics according to any one of [1] to

[11] , which contains ethanol.

[13] A liposome-containing composition for cosmetics according to any one of [1] to

[12] , wherein the ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics is 70% or more.

[14] A cosmetic comprising the liposome-containing composition for cosmetics according to any one of [1] to

[13] . [Effects of the Invention]

[0008] According to one embodiment of the present disclosure, it is possible to provide a liposome-containing composition for cosmetics, which contains liposomes with a high encapsulation rate of an encapsulated substance. According to another embodiment of the present disclosure, a cosmetic can be provided using the liposome-containing composition for cosmetics. DETAILED DESCRIPTION OF THE INVENTION

[0009] Hereinafter, an example of an embodiment of the liposome-containing composition for cosmetics and the cosmetic of the present disclosure will be described in detail. However, the present disclosure is not limited to the following embodiment. In the following embodiment, the components are not essential unless otherwise specified. The same applies to the numerical values ​​and their ranges, and they do not limit the present disclosure.

[0010] In the present disclosure, numerical ranges indicated using "to" include the numerical values ​​before and after "to" as the minimum and maximum values, respectively. In the numerical ranges described in stages in this disclosure, the upper or lower limit value described in one numerical range may be replaced with the upper or lower limit value of another numerical range described in stages. Furthermore, in the numerical ranges described in this disclosure, the upper or lower limit value of that numerical range may be replaced with a value shown in the examples. In the present disclosure, each component may contain multiple corresponding compounds. When multiple substances corresponding to each component are present in the composition, the content of each component means the total content of the multiple substances present in the composition, unless otherwise specified.

[0011] In the present disclosure, a "liposome" is composed of a closed endoplasmic reticulum formed of a lipid bilayer membrane and an encapsulated substance contained within the closed endoplasmic reticulum. In liposomes, a structure with a single lipid bilayer membrane is called a single lamellar structure, and a structure with multiple lipid bilayer membranes is called a multilamellar structure.

[0012] In this disclosure, "cholesterol" is a general term for sterols contained in animals, and "phytosterol" is a general term for sterols contained in plants.

[0013] In the present disclosure, the term "beauty ingredient" refers to an active ingredient that acts on the body, such as the skin, and can have a beauty effect, and is used in cosmetics and the like. The term "water-soluble" means that the solubility in 100 g of water at a temperature of 22° C. and a pH of 7.0 is 0.1 g or more.

[0014] In the present disclosure, the term "average particle size" refers to the volume average particle size determined by dynamic light scattering. Examples of particle size measuring instruments using dynamic light scattering include the concentrated particle size analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.), Nanotrac UPA (manufactured by Nikkiso Co., Ltd.), and the dynamic light scattering particle size distribution measuring instrument LB-550 (manufactured by Horiba, Ltd.). The average particle size is measured by diluting the liposome-containing composition for cosmetics with pure water to 10 times its mass, at room temperature (25°C). The "pure water" used herein is pure water obtained using an ultrapure water production apparatus manufactured by Merck Ltd. The dynamic light scattering method described above can measure the average particle size of liposomes contained in a liposome-containing cosmetic composition. Liposome-containing cosmetic compositions may contain particulate matter other than liposomes. Even in such cases, the average particle size determined by the above method is used as the average particle size of liposomes. When determining the average particle size by the above method, the sample may be filtered through a 230 mesh (pore size: 65 μm) filter before measurement.

[0015] In the present disclosure, the "ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics" is determined by observing the liposomes contained in the liposome-containing composition for cosmetics in an ice-embedded state using a transmission electron microscope (hereinafter also referred to as TEM), and counting the total number of liposomes contained in the liposome-containing composition for cosmetics and the total number of liposomes having a single lamellar structure. More specifically, first, a TEM image of the liposome-containing cosmetic composition is obtained at a magnification of 50,000 times using a TEM. The total number of liposomes present within a circle with a radius of 2 μm and the total number of liposomes having a single lamellar structure are counted at each of three randomly selected points on the TEM image to determine the "ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics." In the present disclosure, the "ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics" is the average value of three points.

[0016] In the present disclosure, the encapsulation rate of liposomes can be comprehensively evaluated based on the "average particle size of liposomes" and the "ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in a liposome-containing composition for cosmetics (hereinafter also referred to as the ratio of liposomes having a single lamellar structure)." For example, when comparing liposomes having a single lamellar structure with liposomes or bicelle structures having a multilamellar structure, if the particle diameters are the same, the area occupied by the lipid membrane portion in the size of each particulate material (i.e., liposomes or bicelle structures) will be smaller, and therefore liposomes having a single lamellar structure will encapsulate a greater amount of encapsulated material. Therefore, if the "average particle diameter of liposomes" is the same, the larger the value of the "ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics," the higher the encapsulation rate of the encapsulated material can be evaluated to be. Furthermore, when comparing liposomes with a single lamellar structure that have different particle sizes, the larger the particle size, the greater the amount of encapsulated material. Therefore, if the "ratio of the total number of liposomes with a single lamellar structure to the total number of liposomes contained in a liposome-containing composition for cosmetics" is the same, it can be evaluated that the larger the "average particle size of the liposomes" is, the higher the encapsulation rate of the encapsulated material.

[0017] <Liposome-containing composition for cosmetics> The liposome-containing cosmetic composition of the present disclosure comprises liposomes and a dispersion medium for dispersing the liposomes, wherein the liposomes comprise stearyl glycyrrhetinate, polyoxyethylene phytosterol, one or more types of compound A selected from the group consisting of cholesterol and phytosterols other than the polyoxyethylene phytosterols, and lecithin, and the liposomes have a single lamellar structure.

[0018] By having the above-mentioned configuration, a liposome-containing cosmetic composition containing liposomes with a high encapsulation rate of encapsulated substances can be obtained. When the liposome-containing composition for cosmetics of the present disclosure is observed using TEM by the method described above, it is inferred that the lipid bilayer membrane of the liposome is formed from stearyl glycyrrhetinate, polyoxyethylene phytosterol, one or more types of compound A selected from the group consisting of cholesterol and phytosterols other than the polyoxyethylene phytosterol, and lecithin. In the liposome-containing composition for cosmetics of the present disclosure, it is presumed that stearyl glycyrrhetinate, polyoxyethylene phytosterol, and compound A, which have similar structures, contribute to the formation of liposomes together with lecithin, as described above, and that the presence of polyoxyethylene phytosterol inhibits the approach of the formed lipid bilayer membranes. As a result, it is presumed that the liposome-containing composition for cosmetics of the present disclosure will have an increased average particle size of the formed liposomes and an increased proportion of liposomes having a single lamellar structure, resulting in liposomes with a high encapsulation rate.

[0019] [Preferred embodiment] From the viewpoint of increasing the encapsulation rate of the encapsulated substance, the average particle size of the liposomes in the liposome-containing composition for cosmetics of the present disclosure is preferably 100 nm to 350 nm. From the viewpoint of increasing the encapsulation rate of the encapsulated substance, the average particle size of the liposomes is more preferably 120 nm or more, even more preferably 140 nm or more, and particularly preferably 160 nm or more. Furthermore, liposomes with large particle sizes tend to aggregate and coalesce over time, resulting in multilamellar formation. Furthermore, liposome-containing cosmetic compositions containing liposomes with large particle sizes tend to show increased turbidity over time. Therefore, from the viewpoint of improving the stability of the liposomes over time, maintaining the encapsulation rate of the encapsulated substance, and suppressing an increase in turbidity of the liposome-containing cosmetic composition, the average particle size of the liposomes is more preferably 300 nm or less, even more preferably 250 nm or less, and particularly preferably 200 nm or less. Furthermore, an average particle size of the liposomes of 350 nm or less tends to improve the permeability of liposome-containing granular materials into the skin, etc. In view of the above, the average particle size of the liposomes is more preferably 120 nm to 300 nm, even more preferably 140 nm to 250 nm, and particularly preferably 160 nm to 200 nm.

[0020] From the viewpoint of increasing the encapsulation rate of the encapsulated substance, in the liposome-containing cosmetic composition of the present disclosure, the content of polyoxyethylene phytosterol relative to the total content of stearyl glycyrrhetinate, polyoxyethylene phytosterol, Compound A, and lecithin (hereinafter also referred to as the total content of the four components) is desirably set to 0.80% by mass to 14% by mass, preferably 3% by mass to 14% by mass. Furthermore, the content of polyoxyethylene phytosterol relative to the total content of the four components is more preferably 3% by mass to 7% by mass, and even more preferably 4% by mass to 7% by mass. When the content of polyoxyethylene phytosterol relative to the total content of the four components is 14% by mass or less, the proportion of liposomes having a single lamellar structure increases, and the encapsulation rate of the encapsulated substance improves. Furthermore, the average particle size of the liposomes can be adjusted by adjusting the content of polyoxyethylene phytosterol relative to the total content of the four components. From the viewpoints of increasing the encapsulation rate of the encapsulated substance and optimizing the average particle size of the liposomes, the content is preferably 3% by mass to 7% by mass, and even more preferably 4% by mass to 7% by mass.

[0021] In the liposome-containing composition for cosmetics of the present disclosure, the content of stearyl glycyrrhetinate relative to the total content of stearyl glycyrrhetinate, polyoxyethylene phytosterol, compound A, and lecithin (i.e., the total content of the four components) is desirably set to 0.3% by mass to 88.0% by mass, and preferably 0.3% by mass to 3% by mass. In particular, from the viewpoint of increasing the proportion of liposomes having a single lamellar structure and improving the encapsulation rate of the encapsulated substance, it is more preferable that the content of stearyl glycyrrhetinate relative to the total content of the four components is 0.3% by mass to 0.7% by mass.

[0022] In the liposome-containing composition for cosmetics of the present disclosure, the ratio of the content of compound A to the content of stearyl glycyrrhetinate is desirably set to 5 to 60 on a mass basis. In particular, from the viewpoint of increasing the proportion of liposomes having a single lamellar structure and improving the encapsulation rate of the encapsulated substance, it is more preferable that the ratio of the content of compound A to the content of stearyl glycyrrhetinate is 10 to 60 by mass.

[0023] From the viewpoint of increasing the encapsulation rate of the encapsulated substance, in the liposome-containing composition for cosmetics of the present disclosure, the ratio of the content of polyoxyethylene phytosterol to the total content of stearyl glycyrrhetinate and compound A is desirably set to 0.0050 to 0.66, and preferably 0.15 to 0.66. The ratio of the content of polyoxyethylene phytosterol to the total content of stearyl glycyrrhetinate and compound A is more preferably 0.16 to 0.35, and even more preferably 0.25 to 0.35, on a mass basis. When the ratio of the polyoxyethylene phytosterol content to the total content of stearyl glycyrrhetinate and compound A is 0.66 or less by mass, the proportion of liposomes having a single lamellar structure increases, and the encapsulation rate of the encapsulated substance improves. From the viewpoint of increasing the encapsulation rate of the encapsulated substance and optimizing the average particle size of the liposomes, the ratio of the polyoxyethylene phytosterol content to the total content of stearyl glycyrrhetinate and compound A is more preferably 0.16 to 0.35 by mass, and even more preferably 0.25 to 0.35.

[0024] From the viewpoint of increasing the encapsulation rate of the encapsulated substance, in the liposome-containing composition for cosmetics of the present disclosure, the ratio of the total content of polyoxyethylene phytosterol and compound A to the total content of stearyl glycyrrhetinate, polyoxyethylene phytosterol, compound A, and lecithin (i.e., the total content of the four components) is desirably set to 3.0% by mass to 32% by mass, preferably 24% by mass to 32% by mass, more preferably 24% by mass to 27% by mass, and even more preferably 25% by mass to 27% by mass. When the ratio of the total content of polyoxyethylene phytosterol and compound A to the total content of the four components is 32% by mass or less, the proportion of liposomes having a single lamellar structure increases, and the encapsulation rate of the encapsulated substance improves. Furthermore, from the viewpoint of increasing the encapsulation rate of the encapsulated substance and optimizing the average particle size of the liposomes, the ratio of the total content of polyoxyethylene phytosterol and compound A to the total content of the four components is more preferably 24% by mass to 27% by mass, and even more preferably 25% by mass to 27% by mass.

[0025] From the viewpoint of ease of production of liposomes (particularly liposomes having a single lamellar structure), the total content of stearyl glycyrrhetinate, polyoxyethylene phytosterol, compound A, and lecithin (i.e., the total content of the four components) relative to the total mass of the liposome-containing composition for cosmetics is preferably 0.10% by mass to 0.90% by mass, more preferably 0.75% by mass to 0.80% by mass, and even more preferably 0.75% by mass to 0.76% by mass.

[0026] [Liposome] In the liposome-containing composition for cosmetics of the present disclosure, the liposomes include liposomes having a single lamellar structure (also called unilamellar vesicles). From the viewpoint of increasing the encapsulation rate of the encapsulated substance, the ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics is preferably 30% or more, more preferably 50% or more, even more preferably 70% or more, and may be 100%. More specifically, from the viewpoint of increasing the encapsulation rate of the encapsulated substance, the ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics is preferably 30% to 100%, more preferably 50% to 100%, and even more preferably 70% to 100%. The liposome-containing cosmetic composition of the present disclosure may contain, as the liposome, a liposome having a multilamellar structure (also called a multilamellar endoplasmic reticulum).

[0027] The liposome contains stearyl glycyrrhetinate, polyoxyethylene phytosterol, one or more compounds A selected from the group consisting of cholesterol and phytosterols other than the polyoxyethylene phytosterols, and lecithin. As described above, these four components are presumed to be contained in the lipid bilayer membrane that constitutes the liposome. Each component will be explained below.

[0028] (Stearyl glycyrrhetinate) Stearyl glycyrrhetinate is a compound that has improved solubility in oils and fats by esterifying stearyl alcohol to glycyrrhetinic acid, and is widely used in the field of cosmetics (i.e., cosmetics and quasi-drugs (e.g., medicated cosmetics)) as an ingredient with anti-inflammatory properties.

[0029] As stearyl glycyrrhetinate, commercially available products can be used. Commercially available stearyl glycyrrhetinate products include, for example, C-O-Grettinol (trade name) manufactured by Maruzen Pharmaceutical Co., Ltd., and Stearyl Glycyrrhetinate (trade name) manufactured by Alps Pharmaceutical Co., Ltd.

[0030] The content of stearyl glycyrrhetinate in the liposome-containing cosmetic composition of the present disclosure may be determined appropriately so as to satisfy the above-mentioned preferred aspects. For example, the content of stearyl glycyrrhetinate relative to the total mass of the liposome composition for cosmetics may be 0.0001% by mass to 0.2% by mass, or 0.0025% by mass to 0.0050% by mass.

[0031] (Polyoxyethylene phytosterol) Polyoxyethylene phytosterols are (CH2CH2-O) n It is a phytosterol having an oxyethylene group represented by the formula: In this disclosure, phytosterols include hydrogenated phytosterols (phytostanols). Specific examples of phytosterols include sitosterol, stigmasterol, fucosterol, spinasterol, brassicasterol, and hydrogenated products thereof.

[0032] From the viewpoint of increasing the encapsulation rate of the encapsulated substance, the average number of moles of oxyethylene groups added in the polyoxyethylene phytosterol is preferably 5 or more, and more preferably 10 or more. Furthermore, by increasing the average number of moles of oxyethylene groups added to the polyoxyethylene phytosterol to 5 or more, the proportion of liposomes having a single lamellar structure can be increased, thereby further improving the encapsulation rate of the liposomes. From the viewpoint of increasing the encapsulation rate of the encapsulated substance, the average number of moles of oxyethylene groups added in the polyoxyethylene phytosterol is preferably 5 to 30, and more preferably 10 to 20. The average number of moles of oxyethylene groups added to polyoxyethylene phytosterol can be measured by known analytical methods such as high performance liquid chromatography (HPLC). When using a commercially available product, the catalog value can be referenced if available.

[0033] As the polyoxyethylene phytosterol, commercially available products can be used. Commercially available polyoxyethylene phytosterols include NIKKOL (registered trademark) BPS-5 (average number of moles of oxyethylene groups added: 5), NIKKOL (registered trademark) BPS-10 (average number of moles of oxyethylene groups added: 10), NIKKOL (registered trademark) BPS-20 (average number of moles of oxyethylene groups added: 20), NIKKOL (registered trademark) BPS-30 (average number of moles of oxyethylene groups added: 30), NIKKOL (registered trademark) BPSH-25 (average number of moles of oxyethylene groups added: 25), all manufactured by Nikko Chemicals Co., Ltd. Examples include EMALEX® PS-5 (average number of moles of oxyethylene groups added: 5), EMALEX® PS-10 (average number of moles of oxyethylene groups added: 10), EMALEX® PS-20 (average number of moles of oxyethylene groups added: 20), EMALEX® PS-30 (average number of moles of oxyethylene groups added: 30), and EMALEX® PS-25 (average number of moles of oxyethylene groups added: 25), all manufactured by Nippon Emulsion Co., Ltd.

[0034] The content of polyoxyethylene phytosterol in the liposome-containing cosmetic composition of the present disclosure may be appropriately determined so as to satisfy the above-mentioned preferred aspects. The content of polyoxyethylene phytosterol relative to the total mass of the liposome cosmetic composition may be 0.00005% by mass to 0.25% by mass, or 0.025% by mass to 0.05% by mass.

[0035] (Compound A: Phytosterol other than cholesterol and polyoxyethylene phytosterol) In this disclosure, cholesterol includes cholestanol and cholesterol derivatives. Examples of cholesterol include cholesterol, dihydrocholesterol, dehydrocholesterol, cholesteryl oleate, cholesteryl isostearate, cholesteryl hydroxystearate, and polyoxyethylene cholesteryl ether. Furthermore, phytosterols other than polyoxyethylene phytosterols refer to phytosterols that do not have a polyoxyethylene group. Furthermore, from the viewpoint of increasing the encapsulation rate of the encapsulated substance, the liposome-containing composition for cosmetics of the present disclosure preferably contains at least cholesterol as compound A.

[0036] The content of compound A in the liposome-containing cosmetic composition of the present disclosure may be determined appropriately so as to satisfy the above-mentioned preferred aspects. The content of compound A relative to the total mass of the liposome cosmetic composition may be 0.003% by mass to 0.2% by mass, or 0.1% by mass to 0.15% by mass. Furthermore, in the present disclosure, the "content of compound A" means the content of cholesterol when the liposome-containing composition for cosmetics contains only cholesterol; when the liposome-containing composition for cosmetics contains only phytosterols other than polyoxyethylene phytosterols, it means the content of the phytosterols; and when the liposome-containing composition for cosmetics contains cholesterol and phytosterols other than polyoxyethylene phytosterols, it means the sum of these contents.

[0037] (lecithin) Examples of lecithin include natural lecithin obtained from plants such as soybean, rapeseed, sunflower, safflower, peanut, cottonseed, corn, rice, and barley, and egg yolk, as well as derivatives thereof (hereinafter also referred to as lecithin derivatives). Examples of lecithin derivatives include hydrogenated lecithin, and compounds in which polyethylene glycol, aminoglycans, etc. are introduced into the phospholipids in lecithin. Among the above, hydrogenated lecithin is particularly preferred from the viewpoint of oxidation stability.

[0038] From the viewpoint of stability over time of the liposome-containing cosmetic composition, the content of phosphatidylcholine relative to the total mass of lecithin (hereinafter also referred to as PC content) is preferably 75% by mass or more, more preferably 80% by mass or more, even more preferably 85% by mass or more, and particularly preferably 90% by mass or more. The PC content can be measured by thin layer chromatography / flame ionization detector (TLC / FID) or high performance liquid chromatography (HPLC).

[0039] Commercially available lecithin can be used. Commercially available lecithin includes COATSOME NC-21 (PC content of 90% by mass or more) manufactured by NOF Corporation, and NIKKOL (registered trademark) Lecithinol S-10E (PC content of 75% by mass to 85% by mass) manufactured by Nikko Chemicals Co., Ltd.

[0040] The content of lecithin in the liposome-containing cosmetic composition of the present disclosure may be appropriately determined so as to satisfy the above-mentioned preferred aspects. The content of lecithin relative to the total mass of the liposome cosmetic composition may be 0.01% by mass to 1.0% by mass, or 0.5% by mass to 0.6% by mass.

[0041] [Inclusions and Dispersion Media] The substance encapsulated in the liposome and the dispersion medium in which the liposome is dispersed will be described below. The liposome preferably encapsulates water, ethanol, a cosmetic ingredient, etc. That is, the encapsulated substances of the liposome include water, ethanol, a cosmetic ingredient, etc. The dispersion medium in which the liposomes are dispersed is not particularly limited as long as it is a dispersion medium in which liposomes can be dispersed, and preferred examples include water and ethanol.

[0042] -water- Examples of water, which is one of the inclusions and water contained in the dispersion medium, include ion-exchanged water, pure water, purified water, and tap water, and among these, purified water is preferred in terms of its applicability to cosmetics.

[0043] The water content relative to the total mass of the liposome-containing cosmetic composition is not particularly limited, but is preferably 1% by mass to 99% by mass, more preferably 10% by mass to 95% by mass, and even more preferably 20% by mass to 90% by mass. In the present disclosure, the "water content relative to the total mass of the liposome-containing composition for cosmetics" refers to the sum of the water content encapsulated in the liposomes and the water content contained in the dispersion medium relative to the total mass of the liposome-containing composition for cosmetics.

[0044] -ethanol- The liposome-containing composition for cosmetics of the present disclosure preferably contains ethanol, from the viewpoint of facilitating the production of liposomes. Ethanol may be contained in the encapsulation material of the liposome (i.e., it may be encapsulated in the liposome), it may be contained in the dispersion medium, or it may be contained in both the encapsulation material and the dispersion medium. As the ethanol, any available ethanol or absolute ethanol can be used.

[0045] From the viewpoint of stability of the liposomes over time, the content of ethanol relative to the total mass of the liposome-containing composition for cosmetics is preferably 0.2% by mass to 30% by mass. Furthermore, the content of ethanol relative to the total mass of the liposome-containing composition for cosmetics may be 1% by mass or more, 3% by mass or more, or 5% by mass or more. Furthermore, the content of ethanol relative to the total mass of the liposome-containing composition for cosmetics may be 25% by mass or less, 20% by mass or less, or 15% by mass or less. In the present disclosure, the "ethanol content relative to the total mass of the liposome-containing composition for cosmetics" refers to the sum of the ethanol content encapsulated in the liposomes and the ethanol content contained in the dispersion medium relative to the total mass of the liposome-containing composition for cosmetics.

[0046] -Beauty ingredients- The liposome preferably encapsulates a cosmetic ingredient. As the cosmetic ingredient, cosmetic ingredients used in the field of cosmetics (that is, cosmetics and quasi-drugs (for example, medicated cosmetics)) can be used. Specific beauty ingredients include tranexamic acid, Sanguisorba officinalis (Bull's Worm) extract, ascorbic acid, ascorbic acid stearate, sodium ascorbate, disodium ascorbate sulfate, aspartic acid, aspartame, acetylglucosamine, acetylglutamic acid, acetylcysteine, acetylpantothenyl ethyl ester, disodium adenosine triphosphate, disodium adenosine monophosphate, ε-aminocaproic acid, γ-aminobutyric acid, allantoin, allantoin-β-glycyrrhetinic acid, albumin, and boar extract. Ingredients: glycerin, erythritol, glucosamine hydrochloride, pyridoxine hydrochloride, hydroxyproline, orotic acid, hydrolyzed elastin, caffeine hydrate, sodium chondroitin sulfate, cyanocobalamin, water-soluble elastin, taurine, sodium palmitoyl methyl taurate, sodium myristoyl methyl taurate, thiamine hydrochloride, theanine, deoxyribonucleic acid, ascorbyl palmitate, pantothenyl alcohol, sodium pantothenate, calcium pantothenate, pyridoxine, phytic acid, placenta extract, flavin adenine diphosphate Nucleotide disodium dihydrate, anhydrous caffeine, riboflavin, riboflavin butyrate, riboflavin phosphate, resorcinol, levulinic acid, glycine, arginine, lysine solution, lauroyl lysine, aspartic acid, palmitoyl aspartic acid, cysteine, methionine, glutamic acid, threonine, serine, tyrosine, histidine, proline, glutathione, salicylic acid, nicotinamide, retinol palmitate, alginic acid, gamma-undecalactone, perilla oil, estradiol, estrone, ergocalciferol Examples of caffeine include ferol, β-carotene, glucosamine, cholecalciferol, tocopheryl acetate, retinol acetate, salicylic acid, shikonin, ascorbyl dipalmitate, pyridoxine dipalmitate, natural vitamin E, α-tocopherol, horse oil, γ-nonalactone, bisabolol, vitamin A oil, hinokitiol, fumaric acid, powdered vitamin A, tocopherol linoleate, δ-tocopherol, tocopherol linoleate, isoleucine, phenylalanine, valine, leucine, and ascorbyl tetra-2-hexyldecanoate. Caffeine includes anhydrous caffeine.

[0047] From the viewpoint of solubility, the cosmetic ingredient encapsulated in the liposome is preferably a water-soluble cosmetic ingredient, and among the above, tranexamic acid, burnetia extract, ascorbic acid, ascorbic acid stearate, sodium ascorbate disodium ascorbate sulfate, aspartic acid, aspartame, acetylglucosamine, acetylglutamic acid, acetylcysteine, acetylpantothenyl ethyl ester, adenosine triphosphate disodium, adenosine monophosphate disodium, ε-aminocaproic acid, γ-aminobutyric acid, allantoin, allantoin β-glycyrrhetinic acid, albumin, inositol, erythritol, glucosamine hydrochloride, pyridoxine hydrochloride, oxyproline, orotic acid, hydrolyzed elastin, caffeine hydrate, sodium chondroitin sulfate, Preferred are cyanocobalamin, water-soluble elastin, taurine, palmitoyl methyl taurate sodium, myristoyl methyl taurate sodium, thiamine hydrochloride, theanine, deoxyribonucleic acid, ascorbyl palmitate, pantothenyl alcohol, sodium pantothenate, calcium pantothenate, pyridoxine, phytic acid, placenta extract, flavin adenine dinucleotide disodium dihydrate, anhydrous caffeine, riboflavin, riboflavin butyrate, riboflavin phosphate, resorcinol, levulinic acid, glycine, arginine, lysine solution, lauroyl lysine, aspartic acid, palmitoyl aspartic acid, cysteine, methionine, glutamic acid, threonine, serine, tyrosine, histidine, proline, glutathione, salicylic acid, and nicotinamide. Furthermore, among the above, one embodiment of the cosmetic ingredient is preferably one or more cosmetic ingredients selected from the group consisting of tranexamic acid and burnet extract, from the viewpoint of providing a whitening effect.

[0048] The content of the cosmetic ingredient relative to the total mass of the liposome-containing cosmetic composition is preferably 0.001 to 5% by mass, more preferably 0.05 to 1.0% by mass, and even more preferably 0.1 to 0.5% by mass. The dispersion medium may contain cosmetic ingredients.

[0049] -Other ingredients- The liposome-containing cosmetic composition of the present disclosure may contain other ingredients such as physiological saline, sugar, a pH adjuster, and a preservative. Examples of sugars include glucose, fructose, lactose, sucrose, trehalose, lactulose, and maltitol. Examples of pH adjusters include sodium hydrogen phosphate, sodium dihydrogen phosphate, anhydrous disodium hydrogen phosphate, sodium hydroxide (caustic soda), citric acid, acetic acid, and triethanolamine. Examples of preservatives include methyl parahydroxybenzoate.

[0050] The pH of the encapsulated substance of the liposome and the dispersion medium is not particularly limited, but is preferably 5 to 9, more preferably 7 to 8. The pH of the encapsulated substance and the dispersion medium can be adjusted by using the above-mentioned pH adjuster.

[0051] [Manufacturing method] A method for producing the liposome-containing cosmetic composition of the present disclosure will be described below, but the method is not limited thereto. The liposome-containing cosmetic composition of the present disclosure can be produced by preparing an oil phase composition and an aqueous phase composition, respectively, mixing the obtained oil phase composition and aqueous phase composition, and then stirring and emulsifying the mixture to form liposomes.

[0052] By mixing, stirring, and emulsifying the oil phase composition and the aqueous phase composition, the oil phase composition and the aqueous phase composition are emulsified into an O / W (oil-in-water) emulsion, and the liposome-containing cosmetic composition of the present disclosure, which contains liposomes and a dispersion medium, is produced.

[0053] Ultrasonic waves or mechanical shearing force can be used as a stirring method. Furthermore, to achieve a uniform particle size, extruder treatment or microfluidizer treatment, in which the mixture is passed through a filter with a specific pore size, can be performed. By performing extruder treatment or the like, multivesicular liposomes containing a plurality of univesicular liposomes can be separated into a plurality of univesicular liposomes.

[0054] The liquid temperature of the mixture can be adjusted as appropriate, but is preferably set to a temperature higher than the phase transition temperature of the lecithin contained in the mixture, for example, 35°C to 70°C.

[0055] In producing the liposome-containing cosmetic composition of the present disclosure, the organic solvent and water may be evaporated from the composition after liposomes have been formed (i.e., the composition containing liposomes). The evaporation mentioned above includes both intentional evaporation of part or all of the organic solvent and water, and natural evaporation of part or all of the organic solvent and water during the stirring and emulsification process.

[0056] When the organic solvent and water are intentionally evaporated, the evaporation method is not particularly limited, and examples thereof include a method of heating the organic solvent and water, a method of leaving the liposome-containing composition for cosmetics to stand, a method of stirring the liposome-containing composition for cosmetics, and a method of vacuum degassing.

[0057] The method for encapsulating a substance (for example, a cosmetic ingredient) into liposomes is not particularly limited, and can be carried out by using an aqueous phase composition in which the cosmetic ingredient is dissolved during emulsification.

[0058] The obtained liposome-containing composition for cosmetics may be subjected to dialysis, filtration, extrusion, or other methods, which can make the average particle size of the liposomes contained therein uniform. Extrusion is a method in which the liposome-containing composition for cosmetics is passed through a filter with fine pores, thereby applying physical shear force to the composition, thereby atomizing the composition. When the liposome-containing composition for cosmetics is passed through the filter, the liposome-containing composition for cosmetics and the filter are kept at a temperature equal to or higher than the phase transition temperature of lecithin, thereby enabling rapid atomization.

[0059] <Cosmetics> The cosmetic preparation of the present disclosure includes the above-described liposome-containing composition for cosmetics of the present disclosure. The cosmetic preparation of the present disclosure may contain the above-described liposome-containing composition for cosmetics of the present disclosure as a part thereof, or may entirely consist of the above-described liposome-containing composition for cosmetics of the present disclosure. In other words, the above-described liposome-containing composition for cosmetics of the present disclosure may be used as a cosmetic preparation as is. When a cosmetic preparation according to the present disclosure includes, as part thereof, the above-described liposome-containing composition for cosmetics according to the present disclosure, the content of the liposome-containing composition for cosmetics according to the present disclosure may be selected, for example, from 0.1% by mass to 10% by mass, or from 1% by mass to 2% by mass, relative to the total mass of the cosmetic preparation according to the present disclosure.

[0060] The form of the cosmetic preparation of the present disclosure is not particularly limited, and may be a liquid, a jelly, a gel, a cream, a solid such as a stick, or a semi-solid. Applications of the cosmetics of the present disclosure include, but are not limited to, skin care cosmetics (skin lotions, emulsions, serums, sunscreens (sunscreens), packs, etc.), body cosmetics (body lotions, body sunscreens, etc.), and scalp cosmetics. The cosmetic preparation of the present disclosure may contain components other than the liposome-containing composition for cosmetics of the present disclosure, depending on the above-mentioned form, use, etc. [Example]

[0061] The above embodiment will be specifically described below using examples, but the above embodiment is not limited to these examples.

[0062] <Example 1-1> (Preparation of Oil Phase Composition) Polyoxyethylene phytosterol A (average number of moles of oxyethylene groups added: 20), hydrogenated lecithin (hydrogenated soybean phospholipid, PC content of 90% or more), cholesterol, ascorbyl tetra-2-hexyldecanoate, stearyl glycyrrhetinate, and absolute ethanol were mixed and dissolved by heating at 60°C for 10 minutes, to obtain oil phase composition X.

[0063] (Preparation of aqueous phase composition) Disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate, tranexamic acid (Maruzen Pharmaceuticals Co., Ltd.), Sanguisorba officinalis extract (Jiyu Extract Powder, Maruzen Pharmaceuticals Co., Ltd.), and purified water were mixed and dissolved by heating at 60°C for 10 minutes to obtain aqueous phase composition Y-1. Methyl parahydroxybenzoate and purified water were mixed and dissolved by heating at 60°C for 10 minutes to obtain aqueous phase composition Y-2.

[0064] (Production of liposome-containing cosmetic composition) The aqueous phase composition Y-1 obtained above was stirred at 3400 rpm (revolutions per minute) using a homomixer while maintaining the temperature at 60°C, and then the oil phase composition X was added to the aqueous phase composition Y-1. After the addition, the mixture of aqueous phase composition Y-1 and oil phase composition X was stirred at 3400 rpm for 45 minutes. After stirring, aqueous phase composition Y-2 was added to the stirred mixture, which was then stirred uniformly for 5 minutes and then cooled to 5°C or below for 35 minutes. After cooling, the mixture was filtered through a 230-mesh filter cloth to obtain a cosmetic composition (liposome-containing cosmetic composition). The content of each component in the cosmetic composition (liposome-containing cosmetic composition) is as shown in Table 1.

[0065] <Examples 1-2 to 1-5> A cosmetic composition (liposome-containing cosmetic composition) was produced in the same manner as in Example 1-1, except that the formulation of the cosmetic composition was changed as shown in Table 1.

[0066] <Comparative Examples 1 and 2> Cosmetic compositions were produced in the same manner as in Example 1-1, except that the components of the cosmetic compositions were changed as shown in Table 1. In Comparative Example 2, no polyoxyethylene phytosterol was used, and therefore the "Polyoxyethylene phytosterol" column in Table 1 is indicated by "-".

[0067] <Examples 2-1 to 2-4> A cosmetic composition (liposome-containing cosmetic composition) was produced in the same manner as in Example 1-1, except that the formulation of the cosmetic composition was changed as shown in Table 2. The polyoxyethylene phytosterol B used in Example 2-1 had an average number of moles of oxyethylene groups added of 5, the polyoxyethylene phytosterol C used in Example 2-2 had an average number of moles of oxyethylene groups added of 10, and the polyoxyethylene phytosterol D used in Example 2-3 had an average number of moles of oxyethylene groups added of 30.

[0068] <<Encapsulation rate evaluation-1 (percentage of liposomes with single lamellar structure)>> The liposomes contained in the cosmetic compositions produced in each example were embedded in ice and TEM images were taken at a magnification of 50,000 times using a transmission electron microscope.

[0069] The total number of liposomes and the total number of liposomes having a single lamellar structure present within a circle of a radius of 2 μm were counted at three randomly selected points on the TEM image, and the average ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics was determined and evaluated based on the following evaluation criteria. From the viewpoint of the encapsulation rate of the encapsulated substance, a higher ratio of liposomes having a single lamellar structure is preferable, and specifically, it is preferably 50% or more. (Evaluation criteria) A: The proportion of liposomes with a single lamellar structure was 70% or more. B: The proportion of liposomes having a single lamellar structure was 50% or more and less than 70%. C: The proportion of liposomes having a single lamellar structure was 30% or more and less than 50%. D: The proportion of liposomes having a single lamellar structure was greater than 0% and less than 30%. E: The percentage of liposomes having a single lamellar structure was 0% (no liposomes having a single lamellar structure were observed).

[0070] <<Encapsulation Rate Evaluation-2 (Average Liposome Particle Diameter)>> The cosmetic composition produced in each example was diluted 10 times by mass with pure water, and the volume average particle size of the contained liposomes was measured by dynamic light scattering using a concentrated particle size analyzer FPAR-1000 (manufactured by Otsuka Electronics Co., Ltd.). The volume average particle size was measured within 20 to 24 hours after the cosmetic composition was produced. The temperature of the measurement environment was 25°C.

[0071] <<Evaluation of stability over time>> The cosmetic compositions produced in each example were filled into 100 mL glass vials, sealed, and left to stand in an environment of 50°C for one week. After standing, the cosmetic composition was diluted 10 times by mass with pure water, and the volume average particle size of the liposomes contained in the liposome-containing cosmetic composition was measured by the method described above. The ratio of the volume average particle diameter of the liposomes contained in the cosmetic composition after standing to the volume average particle diameter of the liposomes contained in the cosmetic composition immediately after production (volume average particle diameter of the liposomes contained in the cosmetic composition after standing / volume average particle diameter of the liposomes contained in the cosmetic composition immediately after production) was determined, and the stability over time of the cosmetic composition was evaluated based on the following evaluation criteria. In Comparative Example 1, no liposomes having a single lamellar structure were observed, and in Comparative Example 2, the proportion of liposomes having a single lamellar structure was small, so evaluation of stability over time was not performed, and the evaluation results are indicated in Table 1 as "-". (Evaluation criteria) The ratio of A:volume average particle size was less than 1.1. B: The ratio of the volume average particle size was 1.1 or more and less than 1.4. C: The ratio of the volume average particle diameter was 1.4 or more.

[0072] The compositions and evaluation results of the cosmetic compositions produced in each example are shown in Tables 1 and 2. For comparison, Example 1-1 is also shown in Table 2. Example 1-1 in Table 2 is the same as Example 1-1 in Table 1. In Tables 1 and 2, the content of polyoxyethylene phytosterol (P) relative to the total content of stearyl glycyrrhetinate (S), polyoxyethylene phytosterol (P), cholesterol or phytosterol (C), and lecithin (R) is expressed as [P / (P+R+C+S)×100] [%]. In Tables 1 and 2, the content of stearyl glycyrrhetinate (S) relative to the total content of stearyl glycyrrhetinate (S), polyoxyethylene phytosterol (P), cholesterol or phytosterol (C), and lecithin (R) is expressed as [S / (P+R+C+S)×100] [%]. In Tables 1 and 2, the ratio of the cholesterol or phytosterol (C) content to the stearyl glycyrrhetinate (S) content is represented by [C / S] [-]. In Tables 1 and 2, the ratio of the content of polyoxyethylene phytosterol (P) to the content of stearyl glycyrrhetinate (S) and cholesterol or phytosterol (C) is expressed as [P / (S+C)] [-]. In Tables 1 and 2, the ratio of the total content of polyoxyethylene phytosterol (P) and cholesterol or phytosterol (C) to the total content of stearyl glycyrrhetinate (S), polyoxyethylene phytosterol (P), cholesterol or phytosterol (C), and lecithin (R) is expressed as [(P+C) / (P+R+C+S)×100] [%].

[0073] [Table 1]

[0074] [Table 2]

[0075] The cosmetic composition obtained in Comparative Example 1 contained stearyl glycyrrhetinate (S), polyoxyethylene phytosterol (P), cholesterol (C), and lecithin (R), but formed disk-shaped structures instead of liposomes. Furthermore, the cosmetic composition obtained in Comparative Example 2 contained stearyl glycyrrhetinate (S), phytosterol (C), and lecithin (R), but did not contain polyoxyethylene phytosterol (P), and although liposomes with a single lamellar structure were formed, the proportion thereof was small.

[0076] On the other hand, it was found that the cosmetic compositions obtained in Examples 1-1 to 1-5 contained stearyl glycyrrhetinate (S), polyoxyethylene phytosterol (P), cholesterol (C), and lecithin (R), and contained liposomes with a single lamellar structure. Furthermore, the cosmetic compositions obtained in Examples 1-1 to 1-5 had a high proportion of liposomes with a single lamellar structure and a large average particle size of the liposomes, and therefore were found to have a higher encapsulation rate of the encapsulated material compared to Comparative Examples 1 and 2.

[0077] The cosmetic compositions obtained in Examples 2-1 to 2-4 also had a high proportion of liposomes with a single lamellar structure and a large average particle size of the liposomes, and therefore, were found to have a higher encapsulation rate of the encapsulated material compared to Comparative Examples 1 and 2. Furthermore, a comparison of Example 1-1 with Examples 2-1 to 2-3 revealed that when polyoxyethylene phytosterol having an average number of added moles of oxyethylene groups of 20 was used, the proportion of liposomes having a single lamellar structure was higher and the encapsulation rate of the encapsulated material was higher than when polyoxyethylene phytosterol having an average number of added moles of oxyethylene groups of 5, 10, or 30 was used. Furthermore, a comparison between Example 1-1 and Example 2-4 revealed that the use of cholesterol as compound A resulted in a higher proportion of liposomes having a single lamellar structure and a higher encapsulation rate of the encapsulated material than the use of phytosterol as compound A.

[0078] Furthermore, it was found that the cosmetic compositions produced in Examples 1-1 to 1-5 and Examples 2-1 to 2-4 all showed little change in the volume average particle size of the liposomes over time, and were excellent in stability over time.

[0079] Below, examples of formulations for cosmetics containing the liposome-containing composition for cosmetics of the present disclosure (cosmetics of the present disclosure) are shown.

[0080] <Example 3-1: Whitening serum> First, a whitening serum Z having the following composition was prepared by a conventional method (total amount 100% by mass). [Composition] [Content (mass%)] Tranexamic acid 2.0 Stearyl Glycyrrhetinate 0.1 1,3-butylene glycol 10.745 Gellan gum 0.05 ·(PEG-240 / Decyltetradeceth-20 / HDI) Copolymer 0.35 Methyl parahydroxybenzoate 0.104 Glyceryl tri-2-ethylhexanoate 4.79 Trimethylglycine 10.0 ·(Sodium acrylate / sodium acroyldimethyltaurate) copolymer 0.75 Phenoxyethanol 0.2 γ-Oryzanol nanoparticles 0.05 Phenoxyethanol (appropriate amount) ·Fragrance trace amount Water remaining

[0081] Next, 2.0% by mass of the water in the composition of the prepared whitening serum Z was replaced with 2.0% by mass of the cosmetic composition of Example 1-1 to obtain a whitening serum (Example 3-1), which is a cosmetic containing the liposome-containing composition for cosmetics of the present disclosure.

Claims

1. Contains liposomes and a dispersion medium for dispersing the liposomes, A liposome-containing composition for cosmetics, wherein the liposome contains stearyl glycyrrhetinate, polyoxyethylene phytosterol, one or more types of compound A selected from the group consisting of cholesterol and phytosterols other than the polyoxyethylene phytosterol, and lecithin, and the liposome has a single lamellar structure, the content of the stearyl glycyrrhetinate relative to the total mass of the liposome-containing composition for cosmetics is 0.0001% by mass to 0.2% by mass, the content of the polyoxyethylene phytosterol relative to the total mass of the liposome-containing composition for cosmetics is 0.00005% by mass to 0.25% by mass, the content of the lecithin relative to the total mass of the liposome-containing composition for cosmetics is 0.01% by mass to 1.0% by mass, The content of the polyoxyethylene phytosterol relative to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin is 3% by mass to 14% by mass.

2. 2. The liposome-containing cosmetic composition according to claim 1, wherein the liposomes have an average particle size of 100 nm to 350 nm.

3. 3. The liposome-containing composition for cosmetics according to claim 1, wherein the average number of moles of oxyethylene groups added in the polyoxyethylene phytosterol is 5 to 30.

4. 4. The liposome-containing composition for cosmetics according to claim 1, wherein the content of the stearyl glycyrrhetinate is 0.3% by mass to 0.7% by mass relative to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin.

5. 5. The liposome-containing composition for cosmetics according to claim 1, wherein the ratio of the content of the compound A to the content of the stearyl glycyrrhetinate is 10 to 60 by mass.

6. 6. The liposome-containing composition for cosmetics according to claim 1, wherein a ratio of the content of the polyoxyethylene phytosterol to the total content of the stearyl glycyrrhetinate and the compound A is 0.15 to 0.66 on a mass basis.

7. 7. The liposome-containing composition for cosmetics according to claim 1, wherein a ratio of the total content of the polyoxyethylene phytosterol and the compound A to the total content of the stearyl glycyrrhetinate, the polyoxyethylene phytosterol, the compound A, and the lecithin is 24% by mass to 27% by mass.

8. The liposome-containing cosmetic composition according to any one of claims 1 to 7, wherein the liposomes encapsulate a cosmetic ingredient.

9. The liposome-containing cosmetic composition according to claim 8 , wherein the cosmetic ingredient is a water-soluble cosmetic ingredient.

10. 10. The liposome-containing composition for cosmetics according to claim 8 or 9, wherein the cosmetic ingredient is one or more cosmetic ingredients selected from the group consisting of tranexamic acid and Sanguisorba officinalis extract.

11. The liposome-containing cosmetic composition according to any one of claims 1 to 10, further comprising ethanol.

12. The liposome-containing composition for cosmetics according to any one of claims 1 to 11, wherein the ratio of the total number of liposomes having a single lamellar structure to the total number of liposomes contained in the liposome-containing composition for cosmetics is 70% or more.

13. A cosmetic comprising the liposome-containing composition for cosmetics according to any one of claims 1 to 12.

Images